In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula

• Published in: International journal of infectious diseases Vol. 99; pp. 253 - 259
• Main Authors: Sonnevend, Ágnes, Ghazawi, Akela, Darwish, Dania, Barathan, Greeshma, Hashmey, Rayhan, Ashraf, Tanveer, Rizvi, Tahir A., Pál, Tibor
• Format: Journal Article
• Language: English
• Published: Canada Elsevier Ltd 01-10-2020; Elsevier
• Subjects: Anti-Bacterial Agents - pharmacology; Azabicyclo Compounds - pharmacology; Aztreonam - pharmacology; Aztreonam-avibactam; Bacterial Proteins; beta-Lactamases - genetics; Carbapenem-resistant Enterobacterales; Carbapenem-Resistant Enterobacteriaceae - drug effects; Carbapenem-Resistant Enterobacteriaceae - genetics; Carbapenems - pharmacology; Ceftazidime - pharmacology; Ceftazidime-avibactam; Colistin; Drug Combinations; Drug Resistance, Bacterial - genetics; Fosfomycin; Fosfomycin - pharmacology; Humans; Microbial Sensitivity Tests; Middle East; Tigecycline - pharmacology; Middle East; Carbapenem-resistant Enterobacterales; Aztreonam-avibactam; Colistin; Ceftazidime-avibactam; Fosfomycin
• ISSN: 1201-9712; 1878-3511
• DOI: 10.1016/j.ijid.2020.07.050

•Colistin and tigecycline resistance is common in CRE in the Arabian Peninsula.•Common metallo-beta-lactamase production impacts ceftazidime-avibactam effectivity.•CRE from the Arabian Peninsula is mostly susceptible to aztreonam-avibactam.•Aztreonam-avibactam resistant non-clonal CRE isolates were encountered.•These were mostly carbapenemase non-producing Escherichia coli.
Our aim was to assess the susceptibility of carbapenem-resistant Enterobacterales (CRE) from the Arabian Peninsula to a broad spectrum of antibiotics, including fosfomycin, ceftazidime-avibactam, and aztreonam-avibactam.
1192 non-repeat CRE isolated in 2009–2017 from 33 hospitals in five countries of the Arabian Peninsula were tested. The minimum inhibitory concentration of 14 antibiotics was determined. Carbapenemase and 16S methylase genes were detected by PCR. Clonality was assessed by PFGE.
The highest rate of susceptibility was detected to aztreonam-avibactam (95.5%) followed by colistin (79.8%), fosfomycin (71.8%) and tigecycline (59.9%). Isolates co-producing two carbapenemases (12.4%) were the least susceptible. Aminoglycoside susceptibility was affected by the frequent production of a 16S methylase. Susceptibility to ceftazidime-avibactam was impacted by the high rate of metallo-beta-lactamase producers (46.3%), while aztreonam-avibactam resistance occurred mostly in clonally unrelated, carbapenemase non-producing Escherichia coli.
Of the currently available drugs: colistin, tigecycline, and ceftazidime-avibactam co-administered with aztreonam appear to be the most effective to treat CRE infections. However, the presence of non-clonal CRE isolates, in which avibactam does not lower the aztreonam MIC below the clinical breakpoint, is of notable concern. Based on the relatively high rate of fosfomycin susceptibility, it would be desirable to license parenteral fosfomycin in the region.